Although anti-calcitonin gene-related peptides are safe and efficacious for adolescents with chronic migraine, access to treatment is often subject to extended insurance authorization delays, ...

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and ...

Citi stated that as the obesity space evolves from injectables to convenient orals, such as orforglipron, the emergence of a ...

Boston Globe via Getty Images Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics represents a strategic move into cardiovascular genetic medicine.

And amid all that, Eli Lilly continues to grow its revenue at a faster pace than any of its comparable peers. In the first quarter, the company's revenue jumped by 45% year over year to $12.7 billion.

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and the risks. Click for my LLY stock update.

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country.

We like it.” Eli Lilly (NYSE:LLY) develops and markets a broad range of pharmaceuticals for conditions such as diabetes, obesity, cancer, autoimmune diseases, and neurological disorders.